Success Stories: EB-1A Approved for Hematology and Medical Oncology Fellow in Nebraska in the Field of Clinical and Translational Medicine
Client’s Testimonial:
Thanks for your excellent work. You are awesome!
General Field: Clinical and Translational Medicine
Position at the Time of Case Filing: Hematology and Medical Oncology Fellow
Country of Origin: India
Service Center: Nebraska Service Center (NSC)
State of Residence at the Time of Filing: Nebraska
Approval Notice Date: July 31st, 2014
Processing Time: 4 months, 11 days
Case Summary:
In this case, the client that we had the opportunity to work with was a Hematology and Medical Oncology Fellow from India in the field of Clinical and Translational Medicine. He had conducted his research in the highly specialized areas of hematology and medical oncology. His work had resulted in 11 peer-reviewed journal articles, 17 abstract publications, numerous conference publication, and 1 book chapter; at the time that his case was filed, his publications had been cited at least 50 times by independent and leading researchers from prestigious institutions and organizations around the world, indicating the major significance of his work. He had also reviewed 12 manuscripts for distinctive, internationally-circulated journals. His superior level of expertise was confirmed in the following quote from an independent recommender, “[Client] found that older patients had an greater chance of having the lymphocyte depleted subtype, and a higher incidence of stage IV disease, all of which contributed to negative prognosis in these patients. [Client] also identified other factors in poor outcomes in elderly patients that need to be investigated by further studies, such as co-morbid illnesses, delay in diagnosis, inadequate adherence to treatment protocols, and failure to maintain dose intensity.” It was our goal to prove that our client qualified for classification as an Alien of Extraordinary Ability given that he sought to remain in the United States to continue work in the area of Clinical and Translational Medicine, and that his continued research would substantially and prospectively benefit the United States. With the proof and documentation that we provided, his case was approved in 4 months and 11 days.